Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2366-1089
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke ; day:16 ; month:1 ; year:2019 ; pages:1-9
Oncology and Therapy ; (16.1.2019), 1-9
- Urheber
-
Belluomini, Lorenzo
Fiorica, Francesco
Frassoldati, Antonio
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40487-019-0092-z
- URN
-
urn:nbn:de:101:1-2019021802414321344179
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Belluomini, Lorenzo
- Fiorica, Francesco
- Frassoldati, Antonio
- SpringerLink (Online service)
Ähnliche Objekte (12)
Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
Potential radiotherapy-related reactivation of immune checkpoint inhibitor hepatitis
Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
Immunophenotyping of peripheral blood in NSCLC patients discriminates responders to immune checkpoint inhibitors
Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis
Immune checkpoint inhibitors alone vs immune checkpoint inhibitors—combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis
Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition
Risk factors of immune checkpoint inhibitor-related pneumonitis after neoadjuvant immunochemotherapy for resectable NSCLC
Prediction of patients’ response to immune checkpoint inhibitors in the treatment of advanced NSCLC
Systemic effects of combination of ablative hypofractionated radiotherapy with immune checkpoint blockade
Photon versus carbon ion radiotherapy – combining radiotherapy with immune checkpoint blockade in the EO771 breast cancer model
Neoadjuvant immune checkpoint inhibitor reduced recurrence in operable NSCLC patients with pathological complete response: a retrospective analysis
Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
Potential radiotherapy-related reactivation of immune checkpoint inhibitor hepatitis
Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
Immunophenotyping of peripheral blood in NSCLC patients discriminates responders to immune checkpoint inhibitors
Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis
Immune checkpoint inhibitors alone vs immune checkpoint inhibitors—combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis
Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition
Risk factors of immune checkpoint inhibitor-related pneumonitis after neoadjuvant immunochemotherapy for resectable NSCLC
Prediction of patients’ response to immune checkpoint inhibitors in the treatment of advanced NSCLC
Systemic effects of combination of ablative hypofractionated radiotherapy with immune checkpoint blockade
Photon versus carbon ion radiotherapy – combining radiotherapy with immune checkpoint blockade in the EO771 breast cancer model
Neoadjuvant immune checkpoint inhibitor reduced recurrence in operable NSCLC patients with pathological complete response: a retrospective analysis
Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
Potential radiotherapy-related reactivation of immune checkpoint inhibitor hepatitis
Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
Immunophenotyping of peripheral blood in NSCLC patients discriminates responders to immune checkpoint inhibitors
Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis
Immune checkpoint inhibitors alone vs immune checkpoint inhibitors—combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis
Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition
Risk factors of immune checkpoint inhibitor-related pneumonitis after neoadjuvant immunochemotherapy for resectable NSCLC
Prediction of patients’ response to immune checkpoint inhibitors in the treatment of advanced NSCLC
Systemic effects of combination of ablative hypofractionated radiotherapy with immune checkpoint blockade
Photon versus carbon ion radiotherapy – combining radiotherapy with immune checkpoint blockade in the EO771 breast cancer model